“Cancer incidence, patterns, and genotype–phenotype associations in individuals with pathogenic or likely pathogenic germline TP53 variants: an observational cohort study” (November 2021). Authored by a strong team of LFS experts that includes members of the LFSA’s Medical Advisory Board and Genetic Counseling Advisory Group is the most recent review of LFS published by The Lancet. The paper is based on those enrolled at the National Cancer Institute’s (NCI) long-term Li-Fraumeni syndrome study based out of the Division of Cancer Epidemiology and Genetics, Clinical Genetics Branch. The team analyzed cancer information compiled on 480 individuals, from 143 families, who have been followed by NCI between 2011 and 2020. Similar to other recent research, the team concluded that there is potential for more individualized cancer screening and risk assessment for those with Li-Fraumeni syndrome.